FindTrial
Sign In

Application of Integrated Metabolomics, Proteomics, and 7T MRI-Based Multimodal Cerebrospinal Fluid Biomarkers in the Diagnosis and Therapeutic Efficacy Prediction of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer

Application of Integrated Metabolomics, Proteomics, and 7T MRI-Based Multimodal Cerebrospinal Fluid Biomarkers in the Diagnosis and Therapeutic Efficacy Prediction of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100041
Enrollment
Unknown
Registered
2025-04-02
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leptomeningeal Metastasis from Non-Small Cell Lung Cancer

Interventions

Non-Small Cell Lung Cancer Leptomeningeal Metastasis Group:none
Non-Small Cell Lung Cancer Group with Suspected Leptomeningeal Metastasis:none

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age =18 years, regardless of gender; 2. Pathologically confirmed NSCLC; 3. Clinically suspected or confirmed LM, meeting any of the following criteria: positive CSF cytology, or 7T MRI indicating leptomeningeal lesions, or presence of LM-related neurological symptoms (such as headache, nausea, vomiting, altered consciousness, cranial nerve palsy, etc.); 4. ECOG performance status score of 0-2; 5. Expected survival >=2 months; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Concurrent other types of malignant tumors or primary central nervous system diseases; 2. Severe cardiac, hepatic, or renal dysfunction, unable to tolerate lumbar puncture or 7T MRI examination; 3. Pregnant or lactating women; 4. Previous brain radiotherapy or meningeal-related surgery that may affect CSF composition; 5. Patients unable to complete follow-up or with poor compliance.

Design outcomes

Primary

MeasureTime frame
Metabolomics;Proteomics;sensitivity;specificity;AUC;—

Countries

China

Contacts

Public ContactWang Yongsheng

West China Hospital of Sichuan University

wangys@scu.edu.cn+86 189 8060 2258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026